Solid Biosciences Inc 's Cash & cash equivalent grew by 56.56 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Solid Biosciences Inc 's Quick Ratio to 20.85, above Solid Biosciences Inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher Quick Ratio than Solid Biosciences Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 361, from total ranking in the first quarter 2026 at 860.

Explain Quick Ratio?
How much Cash & cash equivalents SLDB�s has?
What are SLDB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SLDB Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	6.06 %	8.83 %	15.16 %	48.9 %	83.48 %
Y / Y Cash & cash equivalent Change	122.29 %	24.03 %	26.14 %	38 %	40.91 %
Quick Ratio MRQ	20.85	13.55	5.99	6.94	9.95
SLDB's Total Ranking	# 361	# 860	# 692	# 533	# 469
Seq. Current Liabilities Change	1.74 %	-10.44 %	-7.82 %	26.27 %	4.4 %
Seq. Cash & cash equivalent Change	56.56 %	102.65 %	-20.45 %	-11.92 %	-12.64 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 10
Healthcare Sector	# 53
Overall Market	# 209

Quick Ratio Statistics
High	Average	Low
26.88	10.73	1.68
(Mar 31 2021)		(Sep 30 2020)

Financial Statements
Solid Biosciences Inc 's Current Liabilities	$ 29 Millions	Visit SLDB's Balance sheet
Solid Biosciences Inc 's Cash & cash equivalent	$ 596 Millions	Visit SLDB's Balance sheet
Source of SLDB's Sales		Visit SLDB's Sales by Geography

Cumulative Solid Biosciences Inc 's Quick Ratio

SLDB's Quick Ratio for the trailling 12 Months

SLDB Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	18.68 %	32.95 %	49.35 %	71.74 %	73.28 %
Y / Y Cash & cash equivalent TTM Growth	56.49 %	31.27 %	39.46 %	38.92 %	35.03 %
Quick Ratio TTM	11.47	8.91	8.45	8.42	8.7
Total Ranking TTM	# 354	# 476	# 290	# 260	# 252
Seq. Current Liabilities TTM Growth	1.36 %	1.93 %	3.62 %	10.86 %	13.53 %
Seq. Cash & cash equivalent TTM Growth	30.56 %	7.38 %	4.05 %	7.26 %	9.53 %

Quick ratio ranking by company, industry and sector >> Back to SLDB Financial Strength Comparisons >> Go to Compare SLDB Quick Ratio to its Competitors

News about Solid Biosciences Inc Quick Ratio

Solid Biosciences Announces $109 Million Private Placement, Paving the Way for Revolutionary Genetic Medicines

Solid Biosciences Announces Groundbreaking $109 Million Private Placement for Advancing Precision Genetic Medicines
Charlestown, Mass., Jan. 08, 2024 - Solid Biosciences Inc. (Nasdaq: SLDB), a cutting-edge life sciences company dedicated to developing precision genetic medicines for neuromuscular and cardiac diseases, has made a groundbreaking announcement today. The company revealed that it has successfully entered into a securities purchase agreement with a select group of institutional accredited investors, paving the way for an approximately $108.9 million private placement.
This significant investment will serve as a major boost for Solid Biosciences, propelling their mission to revolutionize the treatment landscape for neuromuscular and cardiac diseases. The private placement is projected to be finalized on or about January 11, 2024, pending the completion of customary closing conditions. The meticulous execution of this partnership highlights Solid Biosciences commitment to adhering to applicable Nasdaq rules, and the pricing of the placement has specifically aimed to meet the Minimum Price requirement set by Nasdaq rules.

On the trailing twelve months basis SLDB Cash & cash equivalent more than doubled by 122.29 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Solid Biosciences Inc 's Quick Ratio to 11.47, above SLDB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Solid Biosciences Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3446.

Explain Quick Ratio?
How much Cash & cash equivalents SLDB�s has?
What are SLDB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 139
Healthcare Sector	# 854
Within the Market	# 361

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.61	5.51	2.27
(Dec 31 2018)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Allogene Therapeutics Inc	35.83	$ 1,136.743 Millions	$ 31.727 Millions
Hemab Therapeutics Holdings Inc	35.34	$ 457.460 Millions	$ 12.944 Millions
Vor Biopharma Inc	33.22	$ 824.374 Millions	$ 24.814 Millions
Lexeo Therapeutics Inc	31.51	$ 494.406 Millions	$ 15.692 Millions
Imagenebio Inc	27.03	$ 177.676 Millions	$ 6.573 Millions
Beam Therapeutics Inc	26.37	$ 2,133.102 Millions	$ 80.883 Millions
Apogee Therapeutics Inc	25.91	$ 971.926 Millions	$ 37.510 Millions
Anavex Life Sciences Corp	24.47	$ 118.326 Millions	$ 4.836 Millions
Artiva Biotherapeutics Inc	23.96	$ 349.400 Millions	$ 14.581 Millions
Palisade Bio Inc	23.86	$ 125.172 Millions	$ 5.246 Millions
Pharmacyte Biotech Inc	23.21	$ 17.838 Millions	$ 0.769 Millions
Cg Oncology Inc	21.77	$ 1,028.278 Millions	$ 47.240 Millions
Instil Bio Inc	21.08	$ 69.678 Millions	$ 3.305 Millions
Solid Biosciences Inc	20.85	$ 595.984 Millions	$ 28.584 Millions
Relay Therapeutics Inc	17.93	$ 910.934 Millions	$ 50.804 Millions
Maze Therapeutics Inc	17.90	$ 411.087 Millions	$ 22.961 Millions
Crispr Therapeutics Ag	17.79	$ 2,364.352 Millions	$ 132.896 Millions
Taysha Gene Therapies Inc	17.53	$ 455.407 Millions	$ 25.975 Millions
Aura Biosciences Inc	16.56	$ 323.840 Millions	$ 19.560 Millions
Kalaris Therapeutics Inc	16.46	$ 143.865 Millions	$ 8.738 Millions
Kyverna Therapeutics Inc	16.10	$ 367.021 Millions	$ 22.802 Millions
Tectonic Therapeutic Inc	15.96	$ 227.068 Millions	$ 14.224 Millions
Candel Therapeutics Inc	15.89	$ 201.565 Millions	$ 12.685 Millions
Inhibikase Therapeutics Inc	15.50	$ 159.019 Millions	$ 10.260 Millions
Voyager Therapeutics Inc	13.75	$ 229.369 Millions	$ 16.685 Millions
Leonabio Inc	13.07	$ 102.167 Millions	$ 7.817 Millions
Lenz Therapeutics Inc	12.82	$ 220.651 Millions	$ 17.212 Millions
X4 Pharmaceuticals Inc	11.41	$ 220.874 Millions	$ 19.366 Millions
Quince Therapeutics Inc	11.30	$ 116.000 Millions	$ 10.262 Millions
Compass Therapeutics Inc	11.15	$ 179.879 Millions	$ 16.128 Millions

Date modified: 2026-09-08T01:25:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.